TY - JOUR AB - © 2015 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd. This review concerns how the primary inflammation preceding the generation of certain key damage-associated molecular patterns (DAMPs) arises in Alzheimer's disease (AD). In doing so, it places soluble amyloid ? (A?), a protein hitherto considered as a primary initiator of AD, in a novel perspective. We note here that increased soluble A? is one of the proinflammatory cytokine-induced DAMPs recognized by at least one of the toll-like receptors on and in various cell types. Moreover, A? is best regarded as belonging to a class of DAMPs, as do the S100 proteins and HMBG1, that further exacerbate production of these same proinflammatory cytokines, which are already enhanced, and induces them further. Moreover, variation in levels of other DAMPs of this same class in AD may explain why normal elderly patients can exhibit high A? plaque levels, and why removing A? or its plaque does not retard disease progression. It may also explain why mouse transgenic models, having been designed to generate high A?, can be treated successfully by this approach. AU - Clark, IA AU - Vissel, B DA - 2015/08/01 DO - 10.1111/bph.13181 EP - 3727 JO - British Journal of Pharmacology PY - 2015/08/01 SP - 3714 TI - Amyloid ?: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease VL - 172 Y1 - 2015/08/01 Y2 - 2024/03/28 ER -